Rapport Therapeutics (NASDAQ:RAPP) Short Interest Update

Rapport Therapeutics (NASDAQ:RAPP) saw a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 1,740,000 shares, a decrease of 17.5% from the October 31st total of 2,110,000 shares. Approximately 10.0% of the company’s shares are short sold. Based on an average daily volume of 147,800 shares, the short-interest ratio is presently 11.8 days.

Hedge Funds Weigh In On Rapport Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Values First Advisors Inc. bought a new position in Rapport Therapeutics during the 3rd quarter valued at about $31,000. BNP Paribas Financial Markets bought a new position in Rapport Therapeutics during the 3rd quarter valued at about $34,000. SG Americas Securities LLC bought a new position in Rapport Therapeutics during the 3rd quarter valued at about $101,000. Sandia Investment Management LP bought a new position in Rapport Therapeutics during the 2nd quarter valued at about $116,000. Finally, MetLife Investment Management LLC purchased a new stake in Rapport Therapeutics in the 3rd quarter valued at about $117,000.

Rapport Therapeutics Stock Performance

Shares of NASDAQ:RAPP opened at $22.84 on Monday. Rapport Therapeutics has a 12 month low of $16.55 and a 12 month high of $29.74. The firm’s 50-day moving average price is $23.12.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.